Importância dos Agonistas Dopaminérgicos nas Fases Inicial e Avançada da Doença de Parkinson
DOI:
https://doi.org/10.34024/rnc.2006.v14.8753Palavras-chave:
Doença de Parkinson, Levodopa, Discinesias, Agonistas DopaminérgicosResumo
O problema bioquímico fundamental da doença de Parkinson (DP) é a deficiência de dopamina, consequência da morte de neurônios da parte compacta da substância negra. Tratamento com levo-dopa é muito eficaz em virtude de sua conversão a dopamina. No entanto, exposição prolongada a esta substância associa-se com o desenvolvimento de flutuações e discinesias em expressivo contigente de pacientes. Evidências atuais indicam
que estas complicações resultam da meia-vida curta da levo-dopa, gerando estimulação pulsátil dos receptores dopaminérgicos. Na fase inicial da DP, monoterapia com agonistas dopaminérgicos que têm meia-vida mais longa reduz pela metade o desenvolvimento de flutuações e virtualmente elimina o aparecimento de discinesias. Quando estas complicações surgem em pacientes já expostos a levo-dopa, o acréscimo de agonistas dopaminérgicos diminui em 30% o número de horas do período off.
Downloads
Métricas
Referências
Piercey MF, Camacho-Ochoa M, Smith MW. Functional roles for dopaminereceptor subtypes. Clin Neuropharmacol 1995;18(suppl):S34-S42.
Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson´s disease. A community-based study. Brain 2000;123:2297-2305.
Calon F, Grondin R, Morissette M, Goulet M, Blanchet PJ, Di Paolo T, et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 2000;47(Suppl 1):S70-S78.
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA. 2000;284:1931-1938.
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A fiveyear study of the incidence of dyskinesia in patients with early Parkinsons disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;342:1484-1491.
Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinsons disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004;18:733-746.
Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, et al. Pergolide versus levodopa monotherapy in early Parkinsonsdisease patients: The PELMOPET study. Mov Disord. 2006;21:343-353.
Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson´s Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, editors. Recent developments in Parkinson´s disease, II. Florham
Park: MacMillan Healthcare Information; 1987, p 293-304.
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653-1661.10. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinsons disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54:93-101.
Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinsons disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-168.
Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F, 043 Study Group. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson´s disease not optimally controlled by L-dopa. J Neural Transm. 2002;109:489-502.
Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinsons disease: 2001 to 2004. Mov Disord 2005;20:523-539.
Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, et al. Levodopa in the treatment of Parkinsons disease: current controversies. Mov Disord 2004;19:997-1005.
Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D, et al. Pramipexole in patients with Parkinsons disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatr 2002;72:713-720.
Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinsons disease: A national multicenter parallel-group randomized study. J Neurol 2006;253:601-607.
Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908-1910.
Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002;287:455-463.
Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004;61:97-102.
Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, et al. Treatment of Parkinsons disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-183.
Rascol O, Pathak A, Bagheri H, Montastruc JL. Dopamine agonists and fibrotic valvular heart disease: further considerations. Mov Disord. 2004;19:1524-1525.
Peralta C, Wolf E, Alber H, Seppi K, Muller S, Bosch S, et al. Valvular heart disease in Parkinsons disease vs. controls: An echocardiographic study. Mov Disord. 2006; 21: 1109-1113.
Downloads
Publicado
Como Citar
Edição
Seção
Publicado: 2006-09-30
Português
English
Español
